Literature DB >> 12569968

Review of the use of botulinum toxin for hyperhidrosis and cosmetic purposes.

Richard G Glogau1.   

Abstract

This article reviews the current status of dermatological uses for botulinum toxin type A (Botox), recently approved in the United States for treatment of glabellar wrinkles, and type B (Myobloc), approved for cervical dystonia. The respective formulations of Botox and Myobloc are described, and injection techniques and special considerations for administration in the treatment of dermatologic conditions are also discussed. The use of botulinum toxin injections for cosmetic treatment of movement-related facial lines and platysmal bands in the neck is reviewed, including injection procedures, efficacy, and potential complications. Recent developments in the use of botulinum toxins for the treatment of palmar and axillary hyperhidrosis are also described, comparing type A and type B results. Although direct comparisons between botulinum toxins for dermatologic applications are complicated by the lack of functional equivalence of the standard potency assays, appropriate dosing strategies for obtaining satisfactory clinical results using type B are being established, which will add to the experience already gained with type A. The diffusion characteristics of type B appear to show different and potentially advantageous clinical profiles in the treatment of crows' feet and hyperhidrosis compared with type A.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12569968     DOI: 10.1097/00002508-200211001-00012

Source DB:  PubMed          Journal:  Clin J Pain        ISSN: 0749-8047            Impact factor:   3.442


  14 in total

Review 1.  Dermacase. Essential or primary hyperhidrosis.

Authors:  Irina Turchin; Benjamin Barankin
Journal:  Can Fam Physician       Date:  2005-04       Impact factor: 3.275

2.  Engineering botulinum neurotoxin to extend therapeutic intervention.

Authors:  Sheng Chen; Joseph T Barbieri
Journal:  Proc Natl Acad Sci U S A       Date:  2009-06-01       Impact factor: 11.205

3.  Botulinum toxin A injection for primary and recurrent chalazia.

Authors:  Tamara Knezevic; Renata Ivekovic; Jasna Pavicic Astalos; Katia Novak Laus; Zdravko Mandic; Aljosa Matejcic
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-11-11       Impact factor: 3.117

4.  Unique substrate recognition mechanism of the botulinum neurotoxin D light chain.

Authors:  Jiubiao Guo; Sheng Chen
Journal:  J Biol Chem       Date:  2013-08-19       Impact factor: 5.157

5.  Botulinum neurotoxin A1 likes it double sweet.

Authors:  Cesare Montecucco; Giuseppe Zanotti
Journal:  Nat Struct Mol Biol       Date:  2016-07-06       Impact factor: 15.369

6.  Time-dependent botulinum neurotoxin serotype A metalloprotease inhibitors.

Authors:  Bing Li; Steven C Cardinale; Michelle M Butler; Ramdas Pai; Jonathan E Nuss; Norton P Peet; Sina Bavari; Terry L Bowlin
Journal:  Bioorg Med Chem       Date:  2011-10-26       Impact factor: 3.641

7.  Analysis of Botulinum Neurotoxin Serotype A Metalloprotease Inhibitors: Analogs of a Chemotype for Therapeutic Development in the Context of a Three-Zone Pharmacophore.

Authors:  James C Burnett; Bing Li; Ramdas Pai; Steven C Cardinale; Michelle M Butler; Norton P Peet; Donald Moir; Sina Bavari; Terry Bowlin
Journal:  Open Access Bioinformatics       Date:  2010-04-01

8.  Iterative structure-based peptide-like inhibitor design against the botulinum neurotoxin serotype A.

Authors:  Jorge E Zuniga; Jared T Hammill; Omri Drory; Jonathan E Nuss; James C Burnett; Rick Gussio; Peter Wipf; Sina Bavari; Axel T Brunger
Journal:  PLoS One       Date:  2010-06-30       Impact factor: 3.240

Review 9.  Clinical uses of botulinum neurotoxins: current indications, limitations and future developments.

Authors:  Sheng Chen
Journal:  Toxins (Basel)       Date:  2012-10-19       Impact factor: 4.546

10.  Endoscopic thoracic sympathectomy for hyperhidrosis: Technique and results.

Authors:  C S Cinà; M M Cinà; C M Clase
Journal:  J Minim Access Surg       Date:  2007-10       Impact factor: 1.407

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.